ClinicalTrials.gov
ClinicalTrials.gov Menu

Cone Beam CT Scanning in Lung and Bladder Cancer.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00469066
Recruitment Status : Completed
First Posted : May 4, 2007
Last Update Posted : February 24, 2016
Sponsor:
Collaborator:
Cross Cancer Institute
Information provided by (Responsible Party):
AHS Cancer Control Alberta

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
To study changes in tumor and normal organ size and/or position which occur during a course of radiation treatments.

Condition or disease
Lung Neoplasm Small Cell Carcinoma Bladder Carcinoma

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Observational
Actual Enrollment : 22 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Improving the Accuracy of Radiotherapy Planning and Delivery Using Kilovoltage Cone Beam CT Imaging
Study Start Date : May 2007
Actual Primary Completion Date : August 2009
Actual Study Completion Date : April 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bladder Cancer

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
primary care clniic
Criteria

Inclusion Criteria:

  • Patient has biopsy proven limited stage SCLC
  • receiving radical concurrent chemoradiotherapy
  • no prior chest RT
  • no prior surgical resection of lung tumor
  • no prior chemotherapy
  • patients' lung tumors should be centrally-located to minimize the effect of respiratory motion
  • patient has biopsy proven TCC bladder
  • receiving radical concurrent chemoradiotherapy or RT alone
  • no prior chemotherapy
  • patient signs study-specific consent form

Exclusion Criteria:

  • mixed small cell and non small cell histology
  • patient not being treated with concurrent chemoradiotherapy
  • chemoradiotherapy given sequentially
  • previous chest RT
  • previous chemotherapy
  • prior surgical resection of lung mass
  • patient ineligible for pelvic RT
  • patient does not sign study consent
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00469066


Locations
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada
Sponsors and Collaborators
AHS Cancer Control Alberta
Cross Cancer Institute
Investigators
Principal Investigator: Don Yee, MD AHS Cancer Control Alberta
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT00469066     History of Changes
Other Study ID Numbers: LU-11-0073
First Posted: May 4, 2007    Key Record Dates
Last Update Posted: February 24, 2016
Last Verified: December 2011

Keywords provided by AHS Cancer Control Alberta:
small cell lung cancer
bladder cancer
conformal radiotherapy

Additional relevant MeSH terms:
Carcinoma
Lung Neoplasms
Urinary Bladder Neoplasms
Carcinoma, Small Cell
Small Cell Lung Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
 Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Urologic Neoplasms
Urogenital Neoplasms
Urinary Bladder Diseases
Urologic Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms